AbbVie to Present Data on Seven Solid Tumor Assets at ESMO 2026 in Madrid

AbbVie will present new and updated data on seven solid tumor assets at the 2026 European Society for Medical Oncology Congress, taking place October 23-27 in Madrid, Spain. The company announced the presentations on October 18, 2026, according to PR Newswire. The data span lung, colorectal, ovarian, prostate and gastric cancers.

AbbVie's Seven Assets at ESMO 2026

AbbVie said the presentations represent its most expansive ESMO program to date. The assets include Temab-A (telisotuzumab adizutecan), ABBV-706, ABBV-969, ABBV-1480 (RC148), alveltamig, Elahere (mirvetuximab soravtansine-gynx) and Emrelis (telisotuzumab vedotin-tllv).

In a Phase 1 study of previously treated advanced colorectal cancer, pooled data from the safety lead-in and dose-optimization cohorts showed Temab-A at 2.4 mg/kg with bevacizumab demonstrated a 30% overall response rate and median overall survival of 14.7 months after a median follow-up of 18.2 months, compared with 10.2 months for standard of care. In non-squamous non-small cell lung cancer, Temab-A showed a 50% overall response rate and median overall survival of 13.8 months in patients with EGFR wild-type disease, and a 63% overall response rate and 16.2-month median overall survival in patients with EGFR-mutant disease.

"The data we are presenting at ESMO reflects the progress being made through AbbVie's disciplined, biology-driven approach to oncology innovation," said Daejin Abidoye, vice president, therapeutic area head of oncology, solid tumor and hematology, AbbVie.

ABBV-706, a SEZ6-directed ADC, achieved a 56% overall response rate and 12.4-month median overall survival at the selected Phase 3 dose of 1.8 mg/kg in 2L+ small cell lung cancer patients. In the 2L-only subset, the overall response rate increased to 82% with a 14.4-month median overall survival.

AbbVie's Oncology Pipeline and Scale

AbbVie is a global biopharmaceutical company developing and commercializing medicines across immunology, oncology, neuroscience, virology, eye care and aesthetics, according to akta.pro company records. The same records show AbbVie reported 12.4% revenue growth to $15.0 billion in Q1 2026 despite a 40.3% decline in legacy Humira sales, and that Skyrizi and Rinvoq combined generated $7.29 billion in Q1 2026, up 16% year over year.

Earlier AbbVie Oncology and Research News

On October 13, 2026, AbbVie received FDA Breakthrough Therapy Designations for Temab-A in colorectal and lung cancer, alongside new data for Skyrizi, Rinvoq and obesity candidate ABBV-295, according to Simply Wall St. On October 15, 2026, AbbVie and Genmab reported positive topline Phase 3 EPCORE DLBCL-2 results for epcoritamab plus R-CHOP in newly diagnosed DLBCL, showing a 51% reduction in disease progression or death versus R-CHOP alone, according to Yahoo. On October 17, 2026, AbbVie presented 20 new scientific abstracts on its IBD portfolio at the 2026 UEG Week in Barcelona, according to Stock Titan.

What Comes Next for AbbVie

AbbVie's Q3 earnings are expected on October 30, according to MarketBeat. The ESMO Congress runs October 23-27 in Madrid.